AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21766559 — intervention group
Group type: EXPERIMENTAL
Intervention: First trimester (0-12 weeks gestation)
Number of subjects: 1435
Study 21766559 — intervention group
Group type: EXPERIMENTAL
Intervention: Third trimester (32-36 weeks gestation)
Number of subjects: 1435
Study 21766559 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum (12-18 weeks)
Number of subjects: 1435
Study 17803665 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Performance Checklist (MPC)
Number of subjects: 339
Study 17803665 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Evaluation of Developmental Status (PEDS)
Number of subjects: 339
Study 16441522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 301
Study 16441522 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 301
Study 15249277 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation (CR)
Number of subjects: 44
Study 15249277 — intervention group
Group type: COMPARATOR
Intervention: Mental Stimulation (MS)
Number of subjects: 44
Study 11747873 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-day 20/75 regimen
Number of subjects: 33
Study 11747873 — intervention group
Group type: COMPARATOR
Intervention: 21-day 30/75 regimen
Number of subjects: 33
Study 11747873 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 33
Study 9576452 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (lansoprazole 30 mg, clarithromycin 500 mg, and amoxicillin 1 gm b.i.d.)
Number of subjects: 352
Study 9576452 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (lansoprazole t.i.d. and amoxicillin t.i.d.)
Number of subjects: 352
Study 9576452 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (lansoprazole b.i.d. and clarithromycin t.i.d.)
Number of subjects: 352
Study 9576452 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (lansoprazole b.i.d. and clarithromycin b.i.d.)
Number of subjects: 352
Study 9576452 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (lansoprazole b.i.d. and amoxicillin t.i.d.)
Number of subjects: 352
Study 9576452 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (lansoprazole)
Number of subjects: 352
Study 9576452 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 352
Study 9576452 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy
Number of subjects: 352
Study 9576452 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 352
Study 9576452 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori negative patients
Number of subjects: 352
Study 9576452 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori positive patients
Number of subjects: 352
Study 9576452 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy and dual therapy
Number of subjects: 352
Study 7887102 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural fentanyl combined with 0.2% bupivacaine
Number of subjects: 21
Study 7887102 — intervention group
Group type: COMPARATOR
Intervention: Patient‐controlled intravenous morphine
Number of subjects: 21
Study 2979269 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated microspheres of pancreatin
Number of subjects: 14
Study 2979269 — intervention group
Group type: COMPARATOR
Intervention: Non-enteric-coated pancreatin with cimetidine
Number of subjects: 14
Study 28444123 — intervention group
Group type: EXPERIMENTAL
Intervention: ANAM4
Number of subjects: 503
Study 28444123 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS‐VS
Number of subjects: 503
Study 28444123 — intervention group
Group type: EXPERIMENTAL
Intervention: CogState
Number of subjects: 503
Study 28444123 — intervention group
Group type: EXPERIMENTAL
Intervention: ImPACT
Number of subjects: 503
Study 28444123 — intervention group
Group type: COMPARATOR
Intervention: NCATs
Number of subjects: 503
Study 24338185 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated packages of care (conventional and complementary) as currently provided in the hospital
Number of subjects: 0
Study 26030027 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-plus-child received intervention (M + C)
Number of subjects: 181
Study 26030027 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-only received intervention (CO)
Number of subjects: 181
Study 26030027 — intervention group
Group type: COMPARATOR
Intervention: Wait list comparison group (CG)
Number of subjects: 181
Study 23348969 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week SMS USA intervention (n = 101)
Number of subjects: 164
Study 23348969 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control group aimed at improving sleep and physical activity (n = 63)
Number of subjects: 164
Study 21498100 — intervention group
Group type: EXPERIMENTAL
Intervention: GH receptor blocker (pegvisomant, 5 mg/day, n=9)
Number of subjects: 20
Study 21498100 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=11)
Number of subjects: 20
Study 18330706 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer L2 experience
Number of subjects: 52
Study 18330706 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter L2 experience
Number of subjects: 52
Study 18330706 — intervention group
Group type: COMPARATOR
Intervention: Attention to word meaning (semantic processing)
Number of subjects: 52
Study 18330706 — intervention group
Group type: COMPARATOR
Intervention: Control condition (non-semantic processing)
Number of subjects: 52
Study 16344317 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy with fludarabine and rituximab
Number of subjects: 88
Study 12679756 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg once daily)
Number of subjects: 665
Study 12679756 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH, 5000 IU 3 times daily)
Number of subjects: 665
Study 12679756 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 665
Study 12679756 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 665
Study 10858919 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbutiamine (Arcalion) 600 mg p.d.
Number of subjects: 0
Study 10858919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8861051 — intervention group
Group type: EXPERIMENTAL
Intervention: B-mode ultrasonographic scanning
Number of subjects: 13500
Study 2405042 — intervention group
Group type: EXPERIMENTAL
Intervention: Injections every 3 months (21 patients)
Number of subjects: 43
Study 2405042 — intervention group
Group type: COMPARATOR
Intervention: Injections every 6 weeks (22 patients)
Number of subjects: 43
Study 6102637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-midwives performing post-partum tubal ligation
Number of subjects: 0
Study 6102637 — intervention group
Group type: COMPARATOR
Intervention: Doctors performing post-partum tubal ligation
Number of subjects: 0
Study 31605616 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Multiple Micronutrient Supplementation (MMS)
Number of subjects: 7486
Study 31279675 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise
Number of subjects: 0
Study 31279675 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study 31279675 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 0
Study 31279675 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 28509605 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio Pox™ (indigenous investigational vaccine)
Number of subjects: 252
Study 28509605 — intervention group
Group type: COMPARATOR
Intervention: Varivax™ (licensed vaccine)
Number of subjects: 252
Study 25534151 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial phone booster call
Number of subjects: 425
Study 25534151 — intervention group
Group type: EXPERIMENTAL
Intervention: Second phone booster call
Number of subjects: 425
Study 25534151 — intervention group
Group type: EXPERIMENTAL
Intervention: First call contact attempts
Number of subjects: 425
Study 25534151 — intervention group
Group type: EXPERIMENTAL
Intervention: Second call contact attempts
Number of subjects: 425
Study 25534151 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of completed calls
Number of subjects: 425
Study 23107810 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose triamcinolone acetate
Number of subjects: 84
Study 23107810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose triamcinolone acetate
Number of subjects: 84
Study 23107810 — intervention group
Group type: COMPARATOR
Intervention: Control (local anesthetic and adrenaline without corticosteroids)
Number of subjects: 84
Study 21601519 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3mg
Number of subjects: 60
Study 21601519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19565411 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) training for GPs
Number of subjects: 265
Study 19565411 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MI training)
Number of subjects: 265
Study 16957432 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1% in combination with benzoyl peroxide/clindamycin
Number of subjects: 35
Study 16957432 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin microsphere 0.04% in combination with benzoyl peroxide/clindamycin
Number of subjects: 35
Study 16957432 — intervention group
Group type: COMPARATOR
Intervention: Tazarotene cream 0.05% in combination with benzoyl peroxide/clindamycin
Number of subjects: 35
Study 15532202 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg, administered 1 hour before sleep for 28 days)
Number of subjects: 40
Study 15532202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11273147 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan therapy
Number of subjects: 0
Study 11273147 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 0
Study 9266391 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral uridine powder at 150 mg/kg per day (divided dose, three times daily)
Number of subjects: 35
Study 9266391 — intervention group
Group type: COMPARATOR
Intervention: Dietary restriction (control group)
Number of subjects: 35
Study 9266391 — intervention group
Group type: EXPERIMENTAL
Intervention: Uridine treatment started prior to age 14 months
Number of subjects: 35
Study 7884218 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 days of intravenous ceftriaxone alone
Number of subjects: 100
Study 7884218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone followed by 100 days of amoxycillin plus probenecid
Number of subjects: 100
Study 7884218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone followed by 100 days of cephadroxil
Number of subjects: 100
Study 7884218 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful treatments
Number of subjects: 100
Study 7884218 — intervention group
Group type: EXPERIMENTAL
Intervention: Final titres less than 30% of the initial titre
Number of subjects: 100
Study 2455152 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (5 mg i.v.)
Number of subjects: 0
Study 2455152 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (10 mg p.o.)
Number of subjects: 0
Study 31410475 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual games (yes)
Number of subjects: 151
Study 31410475 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory games (yes)
Number of subjects: 151
Study 31410475 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined visual and auditory training
Number of subjects: 151
Study 31410475 — intervention group
Group type: COMPARATOR
Intervention: Auditory games (no)
Number of subjects: 151
Study 29475056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy protocol for the prevention of suicide
Number of subjects: 185
Study 27595681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 3850
Study 27595681 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA) 100 mg once daily
Number of subjects: 3850
Study 24682206 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 h sleep deprivation
Number of subjects: 24
Study 24682206 — intervention group
Group type: COMPARATOR
Intervention: 40 h multiple naps
Number of subjects: 24
Study 22075170 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 16114
Study 22075170 — intervention group
Group type: COMPARATOR
Intervention: Control hepatitis A vaccine
Number of subjects: 16114
Study 20961244 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly self-testing at home
Number of subjects: 2922
Study 20961244 — intervention group
Group type: COMPARATOR
Intervention: Monthly high-quality testing in a clinic
Number of subjects: 2922
Study 18178039 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg/70 kg
Number of subjects: 7
Study 18178039 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.12 mg/70 kg
Number of subjects: 7
Study 18178039 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (various doses: 0.00, 0.06, 0.12, and 0.25 mg/70 kg)
Number of subjects: 7
Study 18178039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 16189252 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor letrozole (Lz; 2.5 mg/d)
Number of subjects: 31
Study 16189252 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 31
Study 12556156 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02 malaria vaccine
Number of subjects: 0
Study 12556156 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10984729 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale (GDS)
Number of subjects: 173
Study 10984729 — intervention group
Group type: EXPERIMENTAL
Intervention: Even Briefer Assessment Scale for Depression (EBAS DEP)
Number of subjects: 173
Study 10984729 — intervention group
Group type: EXPERIMENTAL
Intervention: Single question test for depression
Number of subjects: 173
Study 10984729 — intervention group
Group type: COMPARATOR
Intervention: GDS and EBAS DEP
Number of subjects: 173
Study 8666320 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone followed by IFN‐alpha (n = 34)
Number of subjects: 95
Study 8666320 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo followed by IFN‐alpha (n = 30)
Number of subjects: 95
Study 8666320 — intervention group
Group type: COMPARATOR
Intervention: no treatment (control group, n = 31)
Number of subjects: 95
Study 1546838 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-circuit method
Number of subjects: 20
Study 1546838 — intervention group
Group type: COMPARATOR
Intervention: Challenge room method
Number of subjects: 20
Study 3927929 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms
Number of subjects: 6
Study 3927929 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 600 micrograms
Number of subjects: 6
Study 3927929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30066020 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D model No. 1 used in training group A for learning biliary tract anatomy and choledochoscopy techniques
Number of subjects: 20
Study 30066020 — intervention group
Group type: COMPARATOR
Intervention: Virtual 3D image of the same model used in control group B
Number of subjects: 20
Study 25800698 — intervention group
Group type: EXPERIMENTAL
Intervention: eSMART-MH
Number of subjects: 60
Study 25800698 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 60
Study 24467917 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening Families Program for Parents and Youth 10‐14 (SFP 10‐14), consisting of seven sessions and four booster-sessions.
Number of subjects: 288
Study 24467917 — intervention group
Group type: COMPARATOR
Intervention: Minimal 2-hour intervention on parenting delivered in a school setting (Control).
Number of subjects: 288
Study 23038102 — intervention group
Group type: EXPERIMENTAL
Intervention: High output vagus nerve stimulation (20 weeks)
Number of subjects: 41
Study 23038102 — intervention group
Group type: COMPARATOR
Intervention: Low output vagus nerve stimulation (active control, 20 weeks)
Number of subjects: 41
Study 23038102 — intervention group
Group type: EXPERIMENTAL
Intervention: High output vagus nerve stimulation (19 weeks after initial 20 weeks)
Number of subjects: 41
Study 23038102 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline interleukin-6 levels
Number of subjects: 41
Study 23038102 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-1β changes
Number of subjects: 41
Study 20437076 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (n = 15)
Number of subjects: 24
Study 20437076 — intervention group
Group type: COMPARATOR
Intervention: Sham vaccine (n = 9)
Number of subjects: 24
Study 17549475 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD 60 mg/m² (1st cycle), 30 mg/m² (2nd cycle), 45 mg/m² (3rd cycle)
Number of subjects: 15
Study 17549475 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD 30 mg/m² (1st cycle), 60 mg/m² (2nd cycle), 45 mg/m² (3rd cycle)
Number of subjects: 15
Study 17549475 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD (all doses across cycles)
Number of subjects: 15
Study 15920405 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfused trauma patients with microchimerism
Number of subjects: 63
Study 15920405 — intervention group
Group type: COMPARATOR
Intervention: Non-transfused trauma patients and healthy controls
Number of subjects: 63
Study 14507797 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia touchscreen computer (MTS)
Number of subjects: 105
Study 14507797 — intervention group
Group type: COMPARATOR
Intervention: Patient information leaflet (PIL)
Number of subjects: 105
Study 10863615 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (35 mg/kg over 3 days: 1st day: 15 mg/kg; 2nd day: 10 mg/kg; 3rd day: 10 mg/kg)
Number of subjects: 105
Study 10863615 — intervention group
Group type: COMPARATOR
Intervention: Control group (self-medication)
Number of subjects: 105
Study 8779379 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg (Groups B, C, D, E, F)
Number of subjects: 138
Study 8779379 — intervention group
Group type: COMPARATOR
Intervention: No ranitidine (Group A)
Number of subjects: 138
Study 1502972 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (6-week double-blind outpatient trial)
Number of subjects: 75
Study 1502972 — intervention group
Group type: COMPARATOR
Intervention: Control group (no history of substance abuse)
Number of subjects: 75
Study 6627221 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental mastectomy
Number of subjects: 200
Study 6627221 — intervention group
Group type: COMPARATOR
Intervention: Total mastectomy
Number of subjects: 200
Study 6627221 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental mastectomy with resection margin involvement
Number of subjects: 200
Study 6627221 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental mastectomy without resection margin involvement
Number of subjects: 200
Study 30600690 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders + School-located influenza vaccination (SLIV)
Number of subjects: 15768
Study 30600690 — intervention group
Group type: COMPARATOR
Intervention: School-located influenza vaccination (SLIV) alone
Number of subjects: 15768
Study 30085953 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth-Friendly Health Services (YFHS)
Number of subjects: 1000
Study 26920136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk-based beverage (CMBB) containing DHA, PDX, GOS, β-glucan, and other nutrients, consumed 3 servings/day for 28 weeks
Number of subjects: 256
Study 26920136 — intervention group
Group type: COMPARATOR
Intervention: Control cow's milk-based beverage
Number of subjects: 256
Study 24504197 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task condition (climbing while responding to words)
Number of subjects: 0
Study 24504197 — intervention group
Group type: COMPARATOR
Intervention: Single-task condition (climbing without making word associations)
Number of subjects: 0
Study 22326385 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS above the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 15
Study 22326385 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 15
Study 22326385 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 15
Study 20171002 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Sequence Airway (RSA)
Number of subjects: 19
Study 20171002 — intervention group
Group type: COMPARATOR
Intervention: Rapid Sequence Intubation (RSI)
Number of subjects: 19
Study 18520794 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound
Number of subjects: 66
Study 18520794 — intervention group
Group type: COMPARATOR
Intervention: Mediastinoscopy
Number of subjects: 66
Study 15945105 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ischemic preconditioning protocol (n = 10)
Number of subjects: 17
Study 15945105 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group (n = 7)
Number of subjects: 17
Study 12116725 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.28% triclosan/5% pyrophosphate dentifrice
Number of subjects: 186
Study 12116725 — intervention group
Group type: COMPARATOR
Intervention: NaF/silica negative control dentifrice
Number of subjects: 186
Study 10023496 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom intervention
Number of subjects: 178
Study 10023496 — intervention group
Group type: EXPERIMENTAL
Intervention: Home study intervention
Number of subjects: 178
Study 10023496 — intervention group
Group type: COMPARATOR
Intervention: Wait‐list control group
Number of subjects: 178
Study 7605984 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 124
Study 7605984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 2699465 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/die)
Number of subjects: 28
Study 2699465 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (75 mg/die)
Number of subjects: 28